At Legacy Physicians, I believe in empowering patients with knowledge while ensuring their safety through evidence-based, personalized care
GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally
Meanwhile, C-PPS/C nanoparticles were found to inhibit the NF-B pathway to reduce the expression of pro-inflammatory genes (Namgyal et al., 2021)
If VYKAT XR maintains a first-to-market or best-in-class status, it can leverage early relationships with key stakeholders and real-world data to defend and expand its market position
KPV: Limited clinical and preclinical evidence Mechanistic NF-B data Small clinical trials in IBD (oral) and atopic dermatitis (topical/oral) No published subcutaneous human data for systemic effects
Investigating GIPR (ant) agonism: a structural analysis of GIP and its receptor
